Raymond James & Associates Gain Therapeutics, Inc. Call Options Transaction History
Raymond James & Associates
- $150 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GANX
# of Institutions
31Shares Held
3.75MCall Options Held
0Put Options Held
0-
Timelo Investment Management Inc.605KShares$1.2 Million0.45% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.17 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.13 Million0.04% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL450KShares$895,5000.0% of portfolio
-
Hohimer Wealth Management, LLC330KShares$656,7000.1% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $23.6M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...